Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T
CVS Health Corp (NYSE: CVS) announced a new approach called CVS 'CostVantage' that evolves the traditional pharmacy reimbursement model and brings greater transparency and
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.
Ocean Biomedical (NASDAQ: OCEA) announced that its Scientific Co-founder, Jack Elias, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple-negative breast cancer.
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other